XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > Corporate Update AB42, Same OLD Man, D'DOFF and BS

<< Previous

Bullboard Posts

Next >>

Post by SpaceLabson Feb 02, 2022 4:40am

316 Views

Post# 34388055

Corporate Update AB42, Same OLD Man, D'DOFF and BS

Nothing to report but OLD CRAaP again and again. DDOFF has to step down and excelerate DRUG DEVELOPMENT at XRX.
FAILED CEO as far as shareholders are concerned after ROLLBACK and more DILUTION on the way forward .
TOO MUCH on his PLATE to DIGEST, step down DDOFF.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?